Literature DB >> 32544409

Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review.

David I Bernstein1.   

Abstract

Herpes simplex virus (HSV) infections type 1 (HSV-1) and type 2 (HSV-2) are common throughout the world. Infections are lifelong and may produce both acute and recurrent vesiculoulcerative disease as well as more severe diseases. Despite disappointing results from recent HSV vaccine trials new vaccines and more potent antiviral therapies continue to be developed. These newer approaches require initial evaluations in animal models. In this review I have briefly described some of the models available and then more thoroughly describe the guinea pig model of acute and recurrent genital herpes infections. As discussed, the guinea pig model most closely mimics human disease and provides several important endpoints for evaluating vaccines and antivirals.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; Antivirals; Guinea Pig; Herpes simplex virus; Vaccine

Mesh:

Substances:

Year:  2020        PMID: 32544409     DOI: 10.1016/j.antiviral.2020.104821

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  1 in total

1.  The R2 non-neuroinvasive HSV-1 vaccine affords protection from genital HSV-2 infections in a guinea pig model.

Authors:  David I Bernstein; Rhonda D Cardin; Gregory A Smith; Gary E Pickard; Patricia J Sollars; David A Dixon; Rajamouli Pasula; Fernando J Bravo
Journal:  NPJ Vaccines       Date:  2020-11-06       Impact factor: 7.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.